

**In the claims:**

- 1.-6. (canceled)
7. (Currently amended) A drug composition comprising a 2-imidazolyl disulfide and an acceptable carrier, said 2-imidazolyl disulfide being ~~that~~ is useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and ~~a pharmaceutically acceptable carrier.~~
8. (Currently amended) A drug composition comprising a 2-imidazolyl disulfide and an acceptable carrier, said 2-imidazolyl disulfide being ~~that~~ is useful in inhibiting thioredoxin stimulated cell growth and ~~a pharmaceutically acceptable carrier.~~
9. (Currently amended) The drug composition of claim 7, wherein said 2-imidazolyl disulfide ~~compound~~ is 1-methylpropyl 2-imidazolyl disulfide.
10. (Currently amended) The drug composition of claim 8, wherein said 2-imidazolyl disulfide ~~compound~~ is 1-methylpropyl 2-imidazolyl disulfide.
11. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits tumor growth.
12. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits tumor growth.
13. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits thioredoxin.
14. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits thioredoxin.
15. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.
16. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.
17. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide irreversibly binds to Cys<sup>73</sup> of thioredoxin.
18. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide irreversibly binds to Cys<sup>73</sup> of thioredoxin.